These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16160911)

  • 1. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.
    Yang J; Huston L; Berger D; Danke NA; Liu AW; Disis ML; Kwok WW
    J Clin Immunol; 2005 Sep; 25(5):428-36. PubMed ID: 16160911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
    Zeng G; Li Y; El-Gamil M; Sidney J; Sette A; Wang RF; Rosenberg SA; Robbins PF
    Cancer Res; 2002 Jul; 62(13):3630-5. PubMed ID: 12097265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
    Voo KS; Fu T; Heslop HE; Brenner MK; Rooney CM; Wang RF
    Cancer Res; 2002 Dec; 62(24):7195-9. PubMed ID: 12499257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
    Mizote Y; Uenaka A; Isobe M; Wada H; Kakimi K; Saika T; Kita S; Koide Y; Oka M; Nakayama E
    Vaccine; 2014 Feb; 32(8):957-64. PubMed ID: 24397899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex mapping of CD4 T cell epitopes using class II tetramers.
    Yang J; James EA; Huston L; Danke NA; Liu AW; Kwok WW
    Clin Immunol; 2006 Jul; 120(1):21-32. PubMed ID: 16677863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
    Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
    Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
    Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.
    Moro M; Cecconi V; Martinoli C; Dallegno E; Giabbai B; Degano M; Glaichenhaus N; Protti MP; Dellabona P; Casorati G
    BMC Immunol; 2005 Dec; 6():24. PubMed ID: 16329759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.
    Mizote Y; Taniguchi T; Tanaka K; Isobe M; Wada H; Saika T; Kita S; Koide Y; Uenaka A; Nakayama E
    Vaccine; 2010 Jul; 28(32):5338-46. PubMed ID: 20665979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.
    de Waal L; Yüksel S; Brandenburg AH; Langedijk JP; Sintnicolaas K; Verjans GM; Osterhaus AD; de Swart RL
    J Virol; 2004 Feb; 78(4):1775-81. PubMed ID: 14747542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.